Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 9;67(9):7224-7244.
doi: 10.1021/acs.jmedchem.4c00082. Epub 2024 Apr 22.

Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists

Affiliations

Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists

Emil M Ro Rsted et al. J Med Chem. .

Abstract

Classical psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) are showing promising results in clinical trials for a range of psychiatric indications, including depression, anxiety, and substance abuse disorder. These compounds are characterized by broad pharmacological activity profiles, and while the acute mind-altering effects can be ascribed to their shared agonist activity at the serotonin 2A receptor (5-HT2AR), their apparent persistent therapeutic effects are yet to be decidedly linked to activity at this receptor. We report herein the discovery of 2,5-dimethoxyphenylpiperidines as a novel class of selective 5-HT2AR agonists and detail the structure-activity investigations leading to the identification of LPH-5 [analogue (S)-11] as a selective 5-HT2AR agonist with desirable drug-like properties.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing financial interest(s): E.M.R., A.A.J. and J.L.K. are cofounders of and hold equity in Lophora, a startup company pursuing the compound class detailed in this manuscript.

Figures

Figure 1
Figure 1
Structures of 2C-B (1), two of its previously reported conformationally restricted analogues, TCB-2 (2) and DMCPA (3), and the ligands investigated in this study.
Figure 2
Figure 2
2C-B (1) and its 4-, 5-, and 6-membered constrained analogues.
Figure 3
Figure 3
Functional properties exhibited by 1, 4, 5, and 6 at stable 5-HT2AR- and 5-HT2CR-HEK293 cell lines in a Ca2+/Fluo-4 assay. Data are given as mean ± standard deviation (S.D.) values and are from representative experiments performed in duplicate out of at least 3 independent experiments, see Tables 1 and S2.
Figure 4
Figure 4
2C-TFM (18), the N-alkylated analogues 19 and 20, and analogues 2126 with modifications to the 2′ and/or 5′-position substituents.
Figure 5
Figure 5
Functional properties exhibited by 18, (R)-11, and (S)-11 at stable 5-HT2AR- and 5-HT2CR-HEK293 cell lines in a Ca2+/Fluo-4 assay. Concentration–response relationships for 2C-TFM (18), (R)-11, and (S)-11 at 5-HT2AR and 5-HT2CR, and concentration–inhibition relationship for (S)-11 tested in antagonist mode at 5-HT2CR using 5-HT EC90 as agonist (bottom, right). Data are averaged data given as mean ± SEM values based on at least three independent determinations performed in duplicate, see Table S2.
Figure 6
Figure 6
Overview of the functional properties, membrane permeability, Log P, LE, and LLE of LPH-5.
Figure 7
Figure 7
Perspective drawing of (R)-11 as its (2S,3S)-tartaric acid salt (see Supporting Information for full experimental details on crystallography and structure elucidation). Displacement ellipsoids of the nonhydrogen atoms are shown at the 50% probability level. Hydrogen atoms have been shown as spheres of arbitrary size. Nitrogen atoms are in blue, fluorine atoms green, and oxygen atoms red.

Similar articles

Cited by

References

    1. Nichols D. E.; Nichols C. D. Serotonin Receptors. Chem. Rev. 2008, 108 (5), 1614–1641. 10.1021/cr078224o. - DOI - PubMed
    1. McCorvy J. D.; Roth B. L. Structure and function of serotonin G protein-coupled receptors. Pharmacol. Ther. 2015, 150, 129–142. 10.1016/j.pharmthera.2015.01.009. - DOI - PMC - PubMed
    1. Glennon R. A.; Young R.; Rosecrans J. A. Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur. J. Pharmacol. 1983, 91 (2), 189–196. 10.1016/0014-2999(83)90464-8. - DOI - PubMed
    1. Glennon R. A.; Titeler M.; McKenney J. D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984, 35 (25), 2505–2511. 10.1016/0024-3205(84)90436-3. - DOI - PubMed
    1. Carhart-Harris R. L.; Bolstridge M.; Day C. M. J.; Rucker J.; Watts R.; Erritzoe D. E.; Kaelen M.; Giribaldi B.; Bloomfield M.; Pilling S.; et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 2018, 235 (2), 399–408. 10.1007/s00213-017-4771-x. - DOI - PMC - PubMed

Publication types

MeSH terms